|
Toxocara
|
B01.050.500.500.294.400.500.100.780 |
|
|
Space-Time Clustering
|
N06.850.290.600 |
|
|
Length of Stay
|
N02.421.585.400.480 |
|
|
Hospitalization
|
N02.421.585.400 |
|
|
Vibrio
|
B03.440.450.900.859 |
|
|
Electric Stimulation
|
E05.723.402 |
|
|
Glycogen Storage Disease Type V
|
C16.320.565.202.449.560 |
|
|
Cellular Microenvironment
|
D060833 |
[Local surroundings with which cells interact by processing various chemical and physical signals, and by contributing their own effects to this environment.
] |
|
Thermosensing
|
G07.850 |
|
|
Porfiromycin
|
D03.383.097.500.700 |
|
|
Sigmoid Neoplasms
|
C06.405.469.158.356.180.800 |
|
|
Hand-Foot Syndrome
|
D060831 |
[Chemotherapy-induced dermal side effects that are associated with the use of various CYTOSTATIC AGENTS. Symptoms range from mild ERYTHEMA and/or PARESTHESIA to severe ulcerative dermatitis with debilitating pain involving typically palmoplantar and intertriginous areas. These cutaneous manifestations are sometimes accompanied by nail anomalies.
] |
|
Folic Acid Transporters
|
D12.776.157.530.450.074.500.299 |
|
|
Apomixis
|
D060832 |
[Asexual reproduction resulting in the formation of viable seeds from FLOWERS without fertlization (i.e. use of POLLEN). Progeny plants produced from apomictic seeds are perfect clones of the parent.
, A rare form of apomixis in which only pollen (i.e. male gamete) is required to produce viable seeds.
] |
|
Consolidation Chemotherapy
|
D060830 |
[Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.
] |
|
Gadolinium DTPA
|
D02.241.081.018.639.400 |
|
|
Olfactory Marker Protein
|
D12.776.631.653 |
|
|
Road Rage
|
F01.470.093.640.500 |
|
|
Rage
|
F01.470.093.640 |
|
|
Hypromellose Derivatives
|
D09.698.365.180.455 |
|
